Published in Biosci Rep on August 06, 2014
Compartmentalized nitric oxide signaling in the resistance vasculature. Nitric Oxide (2015) 0.80
Nitric oxide: What's new to NO? Am J Physiol Cell Physiol (2016) 0.75
Featured Article: Differential regulation of endothelial nitric oxide synthase phosphorylation by protease-activated receptors in adult human endothelial cells. Exp Biol Med (Maywood) (2016) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
ER-to-Golgi transport visualized in living cells. Nature (1997) 10.24
Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science (1992) 9.01
Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature (1991) 8.41
Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1991) 4.50
Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A (1996) 3.83
Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol (2003) 3.44
Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell (1998) 3.20
Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res (2001) 3.18
Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol (2006) 2.94
Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science (1998) 2.75
Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther (2001) 2.74
Life history of eNOS: partners and pathways. Cardiovasc Res (2007) 2.53
Structural basis for isozyme-specific regulation of electron transfer in nitric-oxide synthase. J Biol Chem (2004) 2.28
Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem (2001) 2.04
Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol (1999) 1.93
The first 35 amino acids and fatty acylation sites determine the molecular targeting of endothelial nitric oxide synthase into the Golgi region of cells: a green fluorescent protein study. J Cell Biol (1997) 1.89
Cloned, expressed rat cerebellar nitric oxide synthase contains stoichiometric amounts of heme, which binds carbon monoxide. Proc Natl Acad Sci U S A (1992) 1.85
Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem (2003) 1.80
An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase. J Biol Chem (1997) 1.73
eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol (2011) 1.60
Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem (2002) 1.56
Evidence for a bidomain structure of constitutive cerebellar nitric oxide synthase. J Biol Chem (1994) 1.43
Mutation of N-myristoylation site converts endothelial cell nitric oxide synthase from a membrane to a cytosolic protein. Circ Res (1993) 1.38
Structural basis for endothelial nitric oxide synthase binding to calmodulin. EMBO J (2003) 1.37
Differences in eNOS activity because of subcellular localization are dictated by phosphorylation state rather than the local calcium environment. J Biol Chem (2005) 1.35
Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release. J Biol Chem (2004) 1.34
Electron transfer by neuronal nitric-oxide synthase is regulated by concerted interaction of calmodulin and two intrinsic regulatory elements. J Biol Chem (2006) 1.32
Apocalmodulin and Ca2+ calmodulin-binding sites on the CaV1.2 channel. Biophys J (2003) 1.26
Ca(2+) sensors of L-type Ca(2+) channel. FEBS Lett (2000) 1.26
Biosynthesis and palmitoylation of endothelial nitric oxide synthase: mutagenesis of palmitoylation sites, cysteines-15 and/or -26, argues against depalmitoylation-induced translocation of the enzyme. Biochemistry (1995) 1.25
Regulation of interdomain interactions by calmodulin in inducible nitric-oxide synthase. J Biol Chem (2009) 1.25
Domain swapping in inducible nitric-oxide synthase. Electron transfer occurs between flavin and heme groups located on adjacent subunits in the dimer. J Biol Chem (1998) 1.24
Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic Biol Med (2006) 1.19
The 42-amino acid insert in the FMN domain of neuronal nitric-oxide synthase exerts control over Ca(2+)/calmodulin-dependent electron transfer. J Biol Chem (1999) 1.17
Disabling a C-terminal autoinhibitory control element in endothelial nitric-oxide synthase by phosphorylation provides a molecular explanation for activation of vascular NO synthesis by diverse physiological stimuli. J Biol Chem (2002) 1.16
Identification of covalently bound amino-terminal myristic acid in endothelial nitric oxide synthase. J Biol Chem (1994) 1.15
Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. Proc Natl Acad Sci U S A (1995) 1.10
Effects of combined phosphorylation at Ser-617 and Ser-1179 in endothelial nitric-oxide synthase on EC50(Ca2+) values for calmodulin binding and enzyme activation. J Biol Chem (2009) 1.08
Autoinhibition of endothelial nitric-oxide synthase. Identification of an electron transfer control element. J Biol Chem (1999) 1.08
Intra-subunit and inter-subunit electron transfer in neuronal nitric-oxide synthase: effect of calmodulin on heterodimer catalysis. J Biol Chem (2001) 1.06
Dissociation of endothelial nitric oxide synthase phosphorylation and activity in uterine artery endothelial cells. Am J Physiol Heart Circ Physiol (2005) 1.04
Role of eNOS phosphorylation at Ser-116 in regulation of eNOS activity in endothelial cells. Vascul Pharmacol (2007) 0.96
Characterization of the roles of the 594-645 region in human endothelial nitric-oxide synthase in regulating calmodulin binding and electron transfer. J Biol Chem (2000) 0.96
Phosphorylation within an autoinhibitory domain in endothelial nitric oxide synthase reduces the Ca(2+) concentrations required for calmodulin to bind and activate the enzyme. Biochemistry (2008) 0.96
Characterization of endothelial nitric-oxide synthase and its reaction with ligand by electron paramagnetic resonance spectroscopy. J Biol Chem (1996) 0.96
Structural elements contribute to the calcium/calmodulin dependence on enzyme activation in human endothelial nitric-oxide synthase. J Biol Chem (2003) 0.94
Nitric oxide alterations following acute ductal constriction in the fetal lamb: a role for superoxide. Am J Physiol Lung Cell Mol Physiol (2010) 0.82
Lobe-specific calcium binding in calmodulin regulates endothelial nitric oxide synthase activation. PLoS One (2012) 0.77
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med (2005) 3.00
C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J (2002) 1.99
Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem (2002) 1.44
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood (2003) 1.39
Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol (2006) 1.32
Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation (2009) 1.30
Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J Immunol (2003) 1.28
15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol (2005) 1.28
Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal Biochem (2003) 1.27
Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med (2007) 1.21
Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res (2007) 1.21
The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway. J Cell Biol (2006) 1.19
Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem (2001) 1.17
Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells (2007) 1.17
Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood (2006) 1.10
Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood (2011) 1.10
The variable number of tandem repeat polymorphism of platelet glycoprotein Ibalpha and risk of coronary heart disease. Blood (2003) 1.08
Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol (2009) 1.07
Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation (2004) 1.05
Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler Thromb Vasc Biol (2002) 1.05
Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation (2002) 1.04
Nestin is essential for zebrafish brain and eye development through control of progenitor cell apoptosis. PLoS One (2010) 1.02
The tumor suppressor DAPK is reciprocally regulated by tyrosine kinase Src and phosphatase LAR. Mol Cell (2007) 1.01
Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology (2011) 1.01
Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation (2002) 1.00
TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding protein-mediated interleukin-6 production. Arterioscler Thromb Vasc Biol (2012) 0.98
Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol (2008) 0.98
Rho kinases regulate the renewal and neural differentiation of embryonic stem cells in a cell plating density-dependent manner. PLoS One (2010) 0.97
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res (2005) 0.96
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis (2007) 0.96
Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway. J Biol Chem (2002) 0.95
Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan. Proc Natl Acad Sci U S A (2012) 0.95
P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. Atherosclerosis (2005) 0.95
Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med (2006) 0.95
14-3-3σ regulates β-catenin-mediated mouse embryonic stem cell proliferation by sequestering GSK-3β. PLoS One (2012) 0.94
Prostaglandin E₂ promotes post-infarction cardiomyocyte replenishment by endogenous stem cells. EMBO Mol Med (2014) 0.94
Structural elements contribute to the calcium/calmodulin dependence on enzyme activation in human endothelial nitric-oxide synthase. J Biol Chem (2003) 0.94
Tumor suppressor death-associated protein kinase is required for full IL-1β production. Blood (2010) 0.94
Molecular basis of estrogen-induced cyclooxygenase type 1 upregulation in endothelial cells. Circ Res (2005) 0.93
Caveolin-1 facilitates cyclooxygenase-2 protein degradation. J Cell Biochem (2010) 0.93
Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study. Blood (2012) 0.91
Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am J Pathol (2011) 0.91
Hyperhomocyst(e)inemia and hemostatic factors: the atherosclerosis risk in communities study. Ann Epidemiol (2002) 0.90
TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood (2004) 0.89
Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts. FASEB J (2002) 0.89
Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways. FASEB J (2007) 0.89
Prostacyclin and PPARα agonists control vascular smooth muscle cell apoptosis and phenotypic switch through distinct 14-3-3 isoforms. PLoS One (2013) 0.87
IRSS: a web-based tool for automatic layout and analysis of IRES secondary structure prediction and searching system in silico. BMC Bioinformatics (2009) 0.86
Prostacyclin receptor signaling and early embryo development in the mouse. Hum Reprod (2007) 0.86
Association of 22q11 deletion with isolated congenital heart disease in three Chinese ethnic groups. Int J Cardiol (2005) 0.86
Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding. Arterioscler Thromb Vasc Biol (2007) 0.86
11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature. Physiol Genomics (2012) 0.86
Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching. Hum Reprod (2004) 0.85
Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-γ, and indoleamine 2,3-dioxygenase. Cell Transplant (2012) 0.85
Exacerbation of oxidative stress-induced cell death and differentiation in induced pluripotent stem cells lacking heme oxygenase-1. Stem Cells Dev (2011) 0.83
Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol (2005) 0.82
Quiescent fibroblasts are more active in mounting robust inflammatory responses than proliferative fibroblasts. PLoS One (2012) 0.82
Environment acidity triggers release of recombinant adeno-associated virus serotype 2 from a tunable matrix. J Control Release (2013) 0.81
Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats. J Med Chem (2009) 0.81
Prostacyclin inhibits endothelial cell XIAP ubiquitination and degradation. J Cell Physiol (2007) 0.80
Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate. J Biol Chem (2005) 0.80
Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol (2002) 0.79
Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. J Med Chem (2010) 0.79
Acute microcirculatory responses induced by skin-surface vibration stimulation at a frequency near the heart rate. Biorheology (2012) 0.79
Isolated congenital heart disease is associated with the 22q11 deletion even though it is rare. Int J Cardiol (2009) 0.79
Human fallopian tubes express prostacyclin (PGI) synthase and cyclooxygenases and synthesize abundant PGI. J Clin Endocrinol Metab (2002) 0.78
Differential effects of mutations in human endothelial nitric oxide synthase at residues Tyr-357 and Arg-365 on L-arginine hydroxylation and GN-hydroxy-L-arginine oxidation. Arch Biochem Biophys (2003) 0.78
Oviduct prostacyclin functions as a paracrine factor to augment the development of embryos. Hum Reprod (2004) 0.78
The ARIC carotid MRI study of blood cellular markers: an inverse association of monocyte myeloperoxidase content with peripheral arterial disease. Angiology (2011) 0.78
Hypercoagulable states and strokes. Curr Atheroscler Rep (2006) 0.78
CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant (2014) 0.77
Lobe-specific calcium binding in calmodulin regulates endothelial nitric oxide synthase activation. PLoS One (2012) 0.77
Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor. J Med Chem (2007) 0.77
The role of RhoA kinase inhibition in human placenta-derived multipotent cells on neural phenotype and cell survival. Biomaterials (2013) 0.76
Two synthetic peptides corresponding to the proximal heme-binding domain and CD1 domain of human endothelial nitric-oxide synthase inhibit the oxygenase activity by interacting with CaM. Arch Biochem Biophys (2009) 0.76
Effect of high-dose methotrexate chemotherapy on intestinal Bifidobacteria, Lactobacillus and Escherichia coli in children with acute lymphoblastic leukemia. Exp Biol Med (Maywood) (2012) 0.75
Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A. Bioorg Med Chem Lett (2007) 0.75
Assessment of coronary heart disease risk by combined analysis of coagulation factors. Atherosclerosis (2008) 0.75
Anti-NSP4 antibody can block rotavirus-induced diarrhea in mice. J Pediatr Gastroenterol Nutr (2008) 0.75
Hybrid CATV/MMW/BB lightwave transmission system based on fiber-wired/fiber-wireless/fiber-VLLC integrations. Opt Express (2015) 0.75
150 m/280 Gbps WDM/SDM FSO link based on OEO-based BLS and afocal telescopes. Opt Lett (2016) 0.75
10 m/25 Gbps LiFi transmission system based on a two-stage injection-locked 680 nm VCSEL transmitter. Opt Lett (2015) 0.75
Essential role of C-Rel in nitric-oxide synthase-2 transcriptional activation: time-dependent control by salicylate. Mol Pharmacol (2006) 0.75